Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

BB Healthcare Trust plc (BBH) Ord GBP0.01

Sell:196.00p Buy:196.40p 0 Change: 2.20p (1.11%)
FTSE 250:0.77%
Market closed Prices as at close on 21 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:196.00p
Buy:196.40p
Change: 2.20p (1.11%)
Market closed Prices as at close on 21 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:196.00p
Buy:196.40p
Change: 2.20p (1.11%)
Market closed Prices as at close on 21 September 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

To provide capital growth and income over the long term, through investment in listed or quoted global healthcare companies. The specific return objectives are to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3-year period and to seek to generate a double-digit total shareholder return p.a. over a rolling 3-year period.
Security Weight
Bristol-Myers Squibb Company 6.43%
Jazz Pharmaceuticals PLC 6.33%
Vertex Pharmaceuticals Inc 5.84%
Anthem Inc 5.36%
Insmed Inc 5.26%
Hill-Rom Holdings Inc 5.16%
Charles River Laboratories International Inc 4.38%
Alnylam Pharmaceuticals Inc 4.29%
Humana AB NPV 4.29%
Bio-Rad Laboratories Inc 3.70%
Sector Weight
Healthcare 51.04%
Country Weight
United States 46.76%
Sweden 4.29%

Fee Structure

Management fee payable monthly in arrear and is at the rate of one-twelfth of 0.95% per calendar month of the Market Capitalisation.There is no performance fee payable to Bellevue. The agreement is terminable on 12 months notice.

Dividend Policy

The Company will set a target dividend each financial year equal to 3.5% of NAV as at the last day of the preceding financial year of the Company.The Company intends to pay dividends on a semi-annual basis, by way of two equal dividends, with dividends declared in July and paid in August and proposed in February/March and paid in March/April in each year.

ASSET SPLIT

Total number of holdings: 0.

Trust Manager

Paul Major

Manager Bio

Paul has 18 years of experience in the healthcare sector on the sell-side and was top-rated by a number of institutional investment clients. He was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included bespoke projects on healthcare portfolio construction for several institutions. Paul was previously an analyst and corporate financier at UBS Warburg and studied biochemistry.

Board Of Directors

Randeep Singh GrewalChairman, Paul Southgate, Josephine Dixon, Katherine Bolsover, Justin Stebbing, Antony Young

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.